Oral and Maxillofacial Surgery, Department of Stomatology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Ann Surg Oncol. 2010 Aug;17(8):2175-83. doi: 10.1245/s10434-010-0996-1. Epub 2010 Mar 12.
Diabetes mellitus (DM) is a prevalent chronic metabolic disease reported to affect the treatment outcomes of malignancies. This study explores the impact of diabetes on the prognosis of oral squamous cell carcinoma (OSCC).
Clinicopathological characteristics and survival in terms of overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) of patients with OSCC who underwent surgical intervention at the Taipei Veterans General Hospital between 2002 and 2005 were stratified by diabetic status and compared.
Patients with DM tend to have a lower OS, RFS, and CSS compared with nondiabetics (adjusted hazard ratio [HR] = 2.22, 2.42, and 2.16, respectively) even in less aggressive tumor stages (stage I and II). In advanced tumors, diabetic patients who were not prescribed adjuvant therapy had a significantly higher recurrence rate than nondiabetic patients (HR = 2.66). However, there was no significant difference in treatment outcome in patients with locally advanced tumors amenable to receive adjuvant therapy, even with the delayed initiation of adjuvant therapy in the DM group (49.1 +/- 22.3 days vs. 40.0 +/- 16.6 days, P = .04). DM was also associated with a higher frequency of perineural invasion (adjusted odds ratio [OR] = 2.53).
DM status could be a prognostic factor for OSCC, particularly for its effect in the survival and perineural invasion. Although diabetes-associated comorbidities may impair decision making toward less aggressive therapeutic modality, adjuvant treatment may be essential for DM patients to improve their survival.
糖尿病(DM)是一种常见的慢性代谢性疾病,据报道会影响恶性肿瘤的治疗效果。本研究探讨了糖尿病对口腔鳞状细胞癌(OSCC)预后的影响。
对 2002 年至 2005 年在台北荣民总医院接受手术治疗的 OSCC 患者的临床病理特征和总生存(OS)、无复发生存(RFS)和癌症特异性生存(CSS)进行分层,根据糖尿病状态进行比较。
与非糖尿病患者相比,DM 患者的 OS、RFS 和 CSS 较低(调整后的危险比[HR]分别为 2.22、2.42 和 2.16),即使在侵袭性较低的肿瘤分期(I 期和 II 期)也是如此。在晚期肿瘤中,未接受辅助治疗的糖尿病患者的复发率明显高于非糖尿病患者(HR = 2.66)。然而,对于可接受辅助治疗的局部晚期肿瘤患者,治疗结果无显著差异,即使 DM 组辅助治疗的开始时间延迟(49.1 +/- 22.3 天比 40.0 +/- 16.6 天,P =.04)。DM 还与更高的神经周围侵犯频率相关(调整后的优势比[OR] = 2.53)。
DM 状态可能是 OSCC 的预后因素,特别是对其生存和神经周围侵犯的影响。尽管糖尿病相关的合并症可能会影响到不那么积极的治疗方式的决策,但辅助治疗对 DM 患者的生存至关重要。